Capstone Therapeutics Corp. (NASDAQ:CAPS) Short Interest Update

Capstone Therapeutics Corp. (NASDAQ:CAPS) was the target of a significant increase in short interest in the month of October. As of October 15th, there was short interest totaling 268,500 shares, an increase of 116.0% from the September 30th total of 124,300 shares. Based on an average daily volume of 2,380,000 shares, the short-interest ratio is presently 0.1 days. Approximately 13.9% of the company’s shares are sold short. Approximately 13.9% of the company’s shares are sold short. Based on an average daily volume of 2,380,000 shares, the short-interest ratio is presently 0.1 days.

Institutional Trading of Capstone Therapeutics

An institutional investor recently bought a new position in Capstone Therapeutics stock. World Investment Advisors purchased a new stake in Capstone Therapeutics Corp. (NASDAQ:CAPS) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 29,000 shares of the company’s stock, valued at approximately $38,000. World Investment Advisors owned approximately 0.40% of Capstone Therapeutics at the end of the most recent reporting period. 2.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Capstone Therapeutics in a report on Tuesday, October 14th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Capstone Therapeutics Stock Performance

CAPS stock opened at $1.02 on Friday. The business’s 50-day moving average price is $1.22 and its two-hundred day moving average price is $1.53. The company has a current ratio of 0.97, a quick ratio of 0.41 and a debt-to-equity ratio of 0.22. The firm has a market cap of $7.44 million, a PE ratio of -1.70 and a beta of -0.81. Capstone Therapeutics has a 1-year low of $0.96 and a 1-year high of $16.18.

Capstone Therapeutics (NASDAQ:CAPS) last posted its earnings results on Friday, August 15th. The company reported ($0.13) earnings per share for the quarter. The business had revenue of $12.85 million during the quarter.

Capstone Therapeutics Company Profile

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism.